RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Subchronic toxicities of four per- and polyfluoroalkyl substances (PFASs) by oral exposure in sprague-dawley rats
Kenyon, E. M., Devito, M. J., Patlewicz, G., Adams, L. D., Thomas, R. S., Ambroso, J. L., Yang, X., Blake, J. C., Upadhyay, B. G., Furr, J., & Hughes, M. F. (2025). Subchronic toxicities of four per- and polyfluoroalkyl substances (PFASs) by oral exposure in sprague-dawley rats. Toxics, 13(7). https://doi.org/10.3390/toxics13070524
PFASs are widely present and persistent in the environment, and exposure can occur via multiple pathways. Human and animal PFAS exposures have been associated with alterations in thyroid hormones, hepatotoxicity, and other adverse effects. This study evaluated the subchronic toxicities of four specific PFASs in 90-day oral rat studies. Studies were conducted in male and female Sprague-Dawley rats exposed to PFASs in corn oil via oral gavage. The PFASs studied were 1H,1H,9H-perfluorononyl acrylate (PFNAC), 1H,1H,2H,2H-perfluorohexyl iodide (PFHI), methyl heptafluoropropyl ketone (MHFPK), and 2-chloro-2,3,3,3-tetrafluoropropanoic acid (CTFPA). High doses were 10 mg/kg-day (male) and 30 mg/kg-day (female) for PFNAC, 200 mg/kg-day for PFHI, 300 mg/kg-day for MHFPK, and 30 (male) and 100 mg/kg-day (female) for CTFPA. The four lower doses for each PFAS were spaced at two- or threefold dose increments. The most consistent effect was dose-dependent increases in the relative and absolute liver weights for PFNAC, PFHI, and CTFPA but not for MHFPK. Increased liver weights were correlated with findings of hepatocellular hypertrophy. Increased kidney weights for PFNAC and PFHI were correlated with increased incidence of minimal tubule epithelial hypertrophy (PFNAC) or increased incidence and severity of chronic progressive nephropathy and hyaline droplet accumulation (PFHI). There were no compound-related effects on morbidity and mortality or overt signs of toxicity.
RTI shares its evidence-based research - through peer-reviewed publications and media - to ensure that it is accessible for others to build on, in line with our mission and scientific standards.